Prevention and control of malaria in pregnancy – new threats, new opportunities?

References

• Rogerson SJ, Hviid L, Duffy PE, et al. Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis. 2007;7:105–117.
   PubMed Web of Science ®Google Scholar
• WHO. WHO policy brief for the implementation of intermittent preventive treatment in malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP) (January 2014). Geneva: World Health Organisation (WHO); 2014.
   Google Scholar
• Kayentao K, Garner P, Van Eijk AM, et al. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. Jama. 2013;309:594–604.
   PubMed Web of Science ®Google Scholar
• Harrington WE, Mutabingwa TK, Kabyemela E, et al. Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin Infect Dis. 2011;53:224–230.
   PubMed Web of Science ®Google Scholar
• Huynh BT, Cottrell G, Cot M, et al. Burden of malaria in early pregnancy: a neglected problem? Clin Infect Dis. 2014;60:598–604.
   PubMed Web of Science ®Google Scholar
• Moore BR, Salman S, Davis TM. Treatment regimens for pregnant women with falciparum malaria. Expert Rev Anti Infect Ther. 2016;14:691–704.
   PubMed Web of Science ®Google Scholar
• Dellicour S, Tatem AJ, Guerra CA, et al. Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. Plos Med. 2010;7:e1000221.
   PubMed Web of Science ®Google Scholar
• Desai M, Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93–104.
   PubMed Web of Science ®Google Scholar
• Walker PG, Ter Kuile FO, Garske T, et al. Estimated risk of placental infection and low birthweight attributable to Plasmodium falciparum malaria in Africa in 2010: a modelling study. Lancet Glob Health. 2014;2:e460–7.
   PubMed Web of Science ®Google Scholar
• Guyatt HL, Snow RW. Malaria in pregnancy as an indirect cause of infant mortality in sub-Saharan Africa. Trans R Soc Trop Med Hyg. 2001;95:569–576.
   PubMed Web of Science ®Google Scholar
• Poespoprodjo JR, Fobia W, Kenangalem E, et al. Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis. 2008;46:1374–1381.
   PubMed Web of Science ®Google Scholar
• McGready R, Lee SJ, Wiladphaingern J, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis. 2012;12:388–396.
   PubMed Web of Science ®Google Scholar
• Nosten F, McGready R, Simpson JA, et al. Effects of Plasmodium vivax malaria in pregnancy. Lancet. 1999;354:546–549.
   PubMed Web of Science ®Google Scholar
• Gething PW, Battle KE, Bhatt S, et al. Declining malaria in Africa: improving the measurement of progress. Malar J. 2014;13:39.
   PubMed Web of Science ®Google Scholar
• Teo A, Hasang W, Randall LM, et al. Decreasing malaria prevalence and its potential consequences for immunity in pregnant women. J Infect Dis. 2014;210:1444–1455.
   PubMed Web of Science ®Google Scholar
• Mayor A, Bardaji A, Macete E, et al. Changing trends in p. falciparum burden, immunity, and disease in pregnancy. N Engl J Med. 2015;373:1607–1617.
   PubMed Web of Science ®Google Scholar
• Rijken MJ, McGready R, Boel ME, et al. Malaria in pregnancy in the Asia-Pacific region. Lancet Infect Dis. 2012;12:75–88.
   PubMed Web of Science ®Google Scholar
• Marfurt J, De Monbrison F, Brega S, et al. Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1. J Infect Dis. 2008;198:409–417.
   PubMed Web of Science ®Google Scholar
• Unger HW, Ome-Kaius M, Wangnapi RA, et al. Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in papua new guinea: a randomised controlled trial. BMC Med. 2015;13:9.
   PubMed Web of Science ®Google Scholar
• White NJ. Intermittent presumptive treatment for malaria. Plos Med. 2005;2:e3.
   PubMed Web of Science ®Google Scholar
• Radeva-Petrova D, Kayentao K, Ter Kuile FO, et al. Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment. Cochrane Database Syst Rev. 2014;10:CD000169.
   Google Scholar
• Eisele TP, Larsen DA, Anglewicz PA, et al. Malaria prevention in pregnancy, birthweight, and neonatal mortality: a meta-analysis of 32 national cross-sectional datasets in Africa. Lancet Infect Dis. 2012;12:942–949.
   PubMed Web of Science ®Google Scholar
• Menendez C, Bardaji A, Sigauque B, et al. Malaria prevention with IPTp during pregnancy reduces neonatal mortality. Plos One. 2010;5:e9438.
   Web of Science ®Google Scholar
• Rogerson SJ, Mwapasa V, Meshnick SR. Malaria in pregnancy: linking immunity and pathogenesis to prevention. Am J Trop Med Hyg. 2007;77:14–22.
   PubMed Web of Science ®Google Scholar
• Lin KJ, Mitchell AA, Yau WP, et al. Safety of macrolides during pregnancy. Am J Obstet Gynecol. 2013;208(221):e1–8.
   Google Scholar
• Berard A, Sheehy O, Zhao JP, et al. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. Pharmacoepidemiol Drug Saf. 2015;24:1241–1248.
   PubMed Web of Science ®Google Scholar
• Chico RM, Hack BB, Newport MJ, et al. On the pathway to better birth outcomes? a systematic review of azithromycin and curable sexually transmitted infections. Expert Rev Anti Infect Ther. 2013;11:1303–1332.
   PubMed Web of Science ®Google Scholar
• van den Broek NR, White SA, Goodall M, et al. The APPLe study: a randomized, community-based, placebo-controlled trial of azithromycin for the prevention of preterm birth, with meta-analysis. Plos Med. 2009;6:e1000191.
   PubMed Web of Science ®Google Scholar
• Luntamo M, Kulmala T, Mbewe B, et al. Effect of repeated treatment of pregnant women with sulfadoxine-pyrimethamine and azithromycin on preterm delivery in Malawi: a randomized controlled trial. Am J Trop Med Hyg. 2010;83:1212–1220.
   PubMed Web of Science ®Google Scholar
• Luntamo M, Kulmala T, Cheung YB, et al. The effect of antenatal monthly sulphadoxine-pyrimethamine, alone or with azithromycin, on foetal and neonatal growth faltering in Malawi: a randomised controlled trial. Trop Med Int Health. 2013;18:386–397.
   PubMed Web of Science ®Google Scholar
• Sidhu AB, Sun Q, Nkrumah LJ, et al. In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. J Biol Chem. 2007;282:2494–2504.
   PubMed Web of Science ®Google Scholar
• Denoeud-Ndam L, Zannou DM, Fourcade C, et al. Cotrimoxazole prophylaxis versus mefloquine intermittent preventive treatment to prevent malaria in HIV-infected pregnant women: two randomized controlled trials. J Acquir Immune Defic Syndr. 2014;65:198–206.
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Mombo-Ngoma G, Ouedraogo S, et al. Intermittent preventive treatment of malaria in pregnancy with mefloquine in hiv-negative women: a multicentre randomized controlled trial. Plos Med. 2014;11:e1001733.
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Desai M, Macete E, et al. Intermittent preventive treatment of malaria in pregnancy with mefloquine in hiv-infected women receiving cotrimoxazole prophylaxis: a multicenter randomized placebo-controlled trial. Plos Med. 2014;11:e1001735.
   PubMed Web of Science ®Google Scholar
• Kimani J, Phiri K, Kamiza S, et al. Efficacy and safety of azithromycin-chloroquine versus sulfadoxine-pyrimethamine for intermittent preventive treatment of plasmodium falciparum malaria infection in pregnant women in africa: an open-label, randomized trial. Plos One. 2016;11:e0157045.
   PubMed Web of Science ®Google Scholar
• Desai M, Gutman J, L’Lanziva A, et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet. 2015;386:2507–2519.
   PubMed Web of Science ®Google Scholar
• Kakuru A, Jagannathan P, Muhindo MK, et al. Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy. N Engl J Med. 2016;374:928–939.
   PubMed Web of Science ®Google Scholar
• Villegas L, McGready R, Htway M, et al. Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, double-blind, placebo-controlled trial. Trop Med Int Health. 2007;12:209–218.
   PubMed Web of Science ®Google Scholar
• Laufer MK, Thesing PC, Eddington ND, et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med. 2006;355:1959–1966.
   PubMed Web of Science ®Google Scholar
• Ohrt C, Willingmyre GD, Lee P, et al. Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 2002;46:2518–2524.
   PubMed Web of Science ®Google Scholar
• Sagara I, Oduro AR, Mulenga M, et al. Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults. Malar J. 2014;13:458.
   PubMed Web of Science ®Google Scholar
• Moore BR, Benjamin JM, Auyeung SO, et al. Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women. Br J Clin Pharmacol. 2016;82:199–212.
   PubMed Web of Science ®Google Scholar
• Group PS, Pekyi D, Ampromfi AA, et al. Four artemisinin-basedtreatments in african pregnant women with malaria. N Engl J Med. 2016;374:913–927.
   PubMed Web of Science ®Google Scholar
• Darpo B, Ferber G, Siegl P, et al. Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria. Br J Clin Pharmacol. 2015;80:706–715.
   PubMed Web of Science ®Google Scholar
• eMC. package leaflet: information for the user. eurartesim 320mg/40mg film-coated tablets. EMC (electronic Medicines Compendium); 2012.
   Google Scholar
• CDC. Update: new recommendations for mefloquine use in pregnancy: centers for disease control and prevention (CDC); 2011 [cited 2016 Aug 1]. Available from: http://www.cdc.gov/malaria/new_info/2011/mefloquine_pregnancy.html
   Google Scholar
• Public Health England. Guidelines for malaria preventation in travellers from the UK 2015: public health england. 2015. [cited 2016 Aug 1]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/461295/2015.09.16_ACMP_guidelines_FINAL.pdf.
   Google Scholar
• Steketee RW, Wirima JJ, Slutsker L, et al. Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: efficacy of chloroquine and mefloquine in rural Malawi. Am J Trop Med Hyg. 1996;55:24–32.
   PubMed Web of Science ®Google Scholar
• Briand V, Bottero J, Noel H, et al. Intermittent treatment for the prevention of malaria during pregnancy in benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. J Infect Dis. 2009;200:991–1001.
   PubMed Web of Science ®Google Scholar
• WHO Malaria Policy Advisory Committee Secretariat. Malaria policy advisory committee to the who: conclusions and recommendations of september 2013 meeting. Malar J. 2013;12:456.
   PubMed Web of Science ®Google Scholar
• Clerk CA, Bruce J, Affipunguh PK, et al. A randomized, controlled trial of intermittent preventive treatment with sulfadoxine-pyrimethamine, amodiaquine, or the combination in pregnant women in Ghana. J Infect Dis. 2008;198:1202–1211.
   PubMed Web of Science ®Google Scholar
• Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet. 2004;364:1428–1434.
   PubMed Web of Science ®Google Scholar
• Manyando C, Njunju EM, D’Alessandro U, et al. Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review. Plos One. 2013;8:e56916.
   PubMed Web of Science ®Google Scholar
• Manyando C, Njunju EM, Mwakazanga D, et al. Safety of daily co-trimoxazole in pregnancy in an area of changing malaria epidemiology: a phase 3b randomized controlled clinical trial. Plos One. 2014;9:e96017.
   Google Scholar
• Benjamin JM, Moore BR, Salman S, et al. Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women. Antimicrob Agents Chemother. 2015;59:4260–4271.
   PubMed Web of Science ®Google Scholar
• Moore KA, Simpson JA, Paw MK, et al. Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study. Lancet Infect Dis. 2016;16:576–583.
   Web of Science ®Google Scholar
• Van Eijk AM, Hill J, Larsen DA, et al. Coverage of intermittent preventive treatment and insecticide-treated nets for the control of malaria during pregnancy in sub-Saharan Africa: a synthesis and meta-analysis of national survey data, 2009-11. Lancet Infect Dis. 2013;13:1029–1042.
   PubMed Web of Science ®Google Scholar
• Menendez C, Ferenchick E, Roman E, et al. Malaria in pregnancy: challenges for control and the need for urgent action. Lancet Glob Health. 2015;3:e433–4.
   PubMed Web of Science ®Google Scholar
• Chico RM, Dellicour S, Roman E, et al. Global call to action: maximize the public health impact of intermittent preventive treatment of malaria in pregnancy in sub-Saharan Africa. Malar J. 2015;14:207.
   PubMed Web of Science ®Google Scholar
• Sridaran S, McClintock SK, Syphard LM, et al. Anti-folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations. Malar J. 2010;9:247.
   PubMed Web of Science ®Google Scholar
• Naidoo I, Roper C. Mapping ‘partially resistant’, ‘fully resistant’, and ‘super resistant’ malaria. Trends Parasitol. 2013;29:505–515.
   PubMed Web of Science ®Google Scholar
• Ter Kuile FO, Van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. Jama. 2007;297:2603–2616.
   PubMed Web of Science ®Google Scholar
• Desai M, Gutman J, Taylor SM, et al. Impact of sulfadoxine-pyrimethamine resistance on effectiveness of intermittent preventive therapy for malaria in pregnancy at clearing infections and preventing low birth weight. Clin Infect Dis. 2016;62:323–333.
   PubMed Web of Science ®Google Scholar
• Harrington WE, Mutabingwa TK, Muehlenbachs A, et al. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc Natl Acad Sci U S A. 2009;106:9027–9032.
   PubMed Web of Science ®Google Scholar
• Minja DT, Schmiegelow C, Mmbando B, et al. Plasmodium falciparum mutant haplotype infection during pregnancy associated with reduced birthweight, Tanzania. Emerg Infect Dis. 2013;19:1448–1454.
   Web of Science ®Google Scholar
• Gutman J, Kalilani L, Taylor S, et al. Plasmodium falciparum dihydropteroate synthetase-A581G mutation reduces effectiveness of sulfadoxine-pyrimethamine preventive therapy in Malawian pregnant women. J Infect Dis. 2015;211:1997–2005.
   PubMed Web of Science ®Google Scholar
• WHO. Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 6 (2014-2015). Geneva: World Health Organisation (WHO); 2015.
   Google Scholar
• malERA Consultative Group on Diagnoses and Diagnostics. A research agenda for malaria eradication: diagnoses and diagnostics. Plos Med. 2011;8:e1000396.
   PubMedGoogle Scholar
• Tagbor H, Bruce J, Agbo M, et al. Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: a randomised controlled non-inferiority trial. Plos One. 2010;5:e14425.
   PubMed Web of Science ®Google Scholar
• Tagbor H, Cairns M, Bojang K, et al. A non-inferiority, individually randomized trial of intermittent screening and treatment versus intermittent preventive treatment in the control of malaria in pregnancy. Plos One. 2015;10:e0132247.
   PubMed Web of Science ®Google Scholar
• Madanitsa M, Kalilani L, Mwapasa V, et al. Scheduled intermittent screening and treatment with dihydroartemisinin-piperaquine versus intermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy in Malawi: an open-label randomized controlled trial. Plos Med. 2016;13:e1002124.
   PubMed Web of Science ®Google Scholar
• Hill J, Hoyt J, Achieng F, et al. User and provider acceptability of intermittent screening and treatment and intermittent preventive treatment with dihydroartemisinin-piperaquine to prevent malaria in pregnancy in Western Kenya. Plos One. 2016;11:e0150259.
   PubMed Web of Science ®Google Scholar
• WHO. Intermittent screening and treatment in pregnancy and the safety of ACTs in the first trimester. Geneva:World Health Organisation (WHO); 2015.
   Google Scholar
• Bhatt S, Weiss DJ, Cameron E, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526:207–211.
   PubMed Web of Science ®Google Scholar
• Gamble C, Ekwaru JP, Ter Kuile FO. Insecticide-treated nets for preventing malaria in pregnancy. Cochrane Database Syst Rev. 2006;(2):CD003755.
   PubMed Web of Science ®Google Scholar
• Hill J, Hoyt J, Van Eijk AM, et al. Prioritizing pregnant women for long-lasting insecticide treated nets through antenatal care clinics. Plos Med. 2014;11:e1001717.
   Google Scholar
• Singh M, Brown G, Rogerson SJ. Ownership and use of insecticide-treated nets during pregnancy in sub-Saharan Africa: a review. Malar J. 2013;12:268.
   PubMed Web of Science ®Google Scholar
• Boene H, Gonzalez R, Vala A, et al. Perceptions of malaria in pregnancy and acceptability of preventive interventions among Mozambican pregnant women: implications for effectiveness of malaria control in pregnancy. Plos One. 2014;9:e86038.
   PubMed Web of Science ®Google Scholar
• Ranson H, Lissenden N. Insecticide resistance in african anopheles mosquitoes: a worsening situation that needs urgent action to maintain malaria control. Trends Parasitol. 2016;32:187–196.
   PubMed Web of Science ®Google Scholar
• Salanti A, Staalsoe T, Lavstsen T, et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol. 2003;49:179–191.
   PubMed Web of Science ®Google Scholar
• Tutterrow YL, Avril M, Singh K, et al. High levels of antibodies to multiple domains and strains of VAR2CSA correlate with the absence of placental malaria in Cameroonian women living in an area of high Plasmodium falciparum transmission. Infect Immun. 2012;80:1479–1490.
   PubMed Web of Science ®Google Scholar
• Dolan G, Ter Kuile FO, Jacoutot V, et al. Bed nets for the prevention of malaria and anaemia in pregnancy. Trans R Soc Trop Med Hyg. 1993;87:620–626.
   PubMed Web of Science ®Google Scholar
• Moore KA, Wiladphaingern J, Cho T, et al. More than four antenatal malaria screens reduces the effects of malaria on adverse pregnancy outcomes. American Society of Tropical Medicine and Hygiene (ASTMH) 64th Annual Meeting; 2015.
   Google Scholar
• Dicko A, Brown JM, Diawara H, et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. Lancet Infect Dis. 2016;16:674–684.
   PubMed Web of Science ®Google Scholar
• Robinson LJ, Wampfler R, Betuela I, et al. In: Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model. PLoS Med. 2015. p. 12:e1001891. doi:10.1371/journal.pmed.1001891.
   Web of Science ®Google Scholar
• Newby G, Hwang J, Koita K, et al. Review of mass drug administration for malaria and its operational challenges. Am J Trop Med Hyg. 2015;93:125–134.
   PubMed Web of Science ®Google Scholar
• WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, chapter 8 - prevention, screening and management of common infection. the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children. Geneva: World Health Organization (WHO); 2013.
   Google Scholar
• Kayentao K, Guirou EA, Doumbo OK, et al. Preliminary study of quinine pharmacokinetics in pregnant women with malaria-HIV co-infection. Am J Trop Med Hyg. 2014;90:530–534.
   PubMed Web of Science ®Google Scholar
• Byakika-Kibwika P, Lamorde M, Mayito J, et al. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother. 2012;67:2213–2221.
   PubMed Web of Science ®Google Scholar
• Kredo T, Mauff K, Workman L, et al. The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients. BMC Infect Dis. 2016;16:30.
   PubMed Web of Science ®Google Scholar
• Schlagenhauf P, Hatz C, Behrens R, et al. Mefloquine at the crossroads? implications for malaria chemoprophylaxis in Europe. Travel Med Infect Dis. 2015;13:192–196.
   PubMed Web of Science ®Google Scholar
• Bloechliger M, Schlagenhauf P, Toovey S, et al. Malaria chemoprophylaxis regimens: a descriptive drug utilization study. Travel Med Infect Dis. 2014;12:718–725.
   PubMed Web of Science ®Google Scholar
• CDC. Choosing a drug to prevent malaria: centers for disease control and prevention (CDC); 2016 [cited 2016 Jul 24]. Available from: https://www.cdc.gov/malaria/travelers/drugs.html.
   Google Scholar
• Cross R, Ling C, Day NP, et al. Revisiting doxycycline in pregnancy and early childhood–time to rebuild its reputation? Expert Opin Drug Saf. 2016;15:367–382.
   PubMed Web of Science ®Google Scholar
• Mutabingwa TK, Bolla MC, Li JL, et al. Maternal malaria and gravidity interact to modify infant susceptibility to malaria. Plos Med. 2005;2:e407.
   PubMed Web of Science ®Google Scholar
• Moro L, Bardaji A, Nhampossa T, et al. Malaria and HIV infection in mozambican pregnant women are associated with reduced transfer of antimalarial antibodies to their newborns. J Infect Dis. 2014;211:1004–1014.
   PubMed Web of Science ®Google Scholar
• McLean AR, Ataide R, Simpson JA, et al. Malaria and immunity during pregnancy and postpartum: a tale of two species. Parasitology. 2015;142:999–1015.
   PubMed Web of Science ®Google Scholar
• Teo A, Hasang W, Randall LM, et al. Malaria preventive therapy in pregnancy and its potential impact on immunity to malaria in an area of declining transmission. Malar J. 2015;14:215.
   PubMed Web of Science ®Google Scholar
• Babakhanyan A, Tutterrow YL, Bobbili N, et al. Influence of intermittent preventive treatment on antibodies to VAR2CSA in pregnant cameroonian women. Am J Trop Med Hyg. 2016;94:640–649.
   PubMed Web of Science ®Google Scholar
• Unger HW, Wangnapi RA, Ome-Kaius M, et al. Azithromycin-containing intermittent preventive treatment in pregnancy affects gestational weight gain, an important predictor of birthweight in Papua New Guinea - an exploratory analysis. Matern Child Nutr. 2016;12:699–712.
   PubMed Web of Science ®Google Scholar
• Khan I, Azhar EI, Abbas AT, et al. Metagenomic analysis of antibiotic-induced changes in gut microbiota in a pregnant rat model. Front Pharmacol. 2016;7:104.
   PubMed Web of Science ®Google Scholar
• Van Eijk AM, Hill J, Noor AM, et al. Prevalence of malaria infection in pregnant women compared with children for tracking malaria transmission in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2015;3:e617–28.
   Google Scholar
• WHO. Eliminating Malaria. Geneva: World Health Organization (WHO); 2016.
   Google Scholar